Skip to main content
. Author manuscript; available in PMC: 2014 Mar 19.
Published in final edited form as: ACS Chem Biol. 2012 Jan 19;7(3):526–534. doi: 10.1021/cb200439z

Figure 4.

Figure 4

Viral plaque inhibition of candidates identified by FP. (▼) DMSO negative control (0% inhibition), (♦) oseltamivir carboxylate positive control (100% inhibition), (○) Compound 16 (IC50 >100 μM), (□) Compound 43 (IC50 >100 μM), (∆) Compound 31 (IC50 >50 μM), (◊) No infection, (●) Compound 42 (IC50 = 14.28 ± 0.07 μM), (▽) Compound 44 (IC50 = 18.61 ± 0.09 μM), (■) Compound 45 (IC50 = 12.68 ± 0.08μM), (▲) Compound 2 (IC50 = 3.13 ± 0.08 μM).